Kishore K, Jailakhani B L, Sharma J N, Ahuja G K
Indian J Physiol Pharmacol. 1986 Apr-Jun;30(2):171-6.
Four brands of phenytoin were studied in 60 newly diagnosed epileptic patients randomly and equally placed in 4 groups. Serum phenytoin levels were estimated by EMIT and spectrophotometric methods both of which gave close values with good correlation (r = 0.985). Average serum levels and the incidence of remission achieved with the 4 brands varied within statistical scatter; thus these 4 brands manifested equivalent therapeutic efficacy. In 22 patients serum level was less than 5 micrograms/ml, in 9 of whom attacks remained uncontrolled. In 38 patients serum level exceeded 5 micrograms/ml in 2 of whom attacks were uncontrolled. In 44 out of 60 patients the 2 weeks serum levels were significantly higher (P less than 0.001 by paired t-test) than those after 3 months. In the remaining 16 patients the serum levels at 3 months were significantly higher than at 2 weeks levels (P less than 0.01).
对60例新诊断的癫痫患者进行了研究，将他们随机且平均分为4组，分别使用4种品牌的苯妥英钠。采用酶放大免疫测定技术（EMIT）和分光光度法测定血清苯妥英水平，两种方法得出的值相近，相关性良好（r = 0.985）。4种品牌的平均血清水平及缓解率在统计学离散范围内有所不同；因此，这4种品牌表现出同等的治疗效果。22例患者的血清水平低于5微克/毫升，其中9例发作仍未得到控制。38例患者的血清水平超过5微克/毫升，其中2例发作未得到控制。60例患者中有44例在2周时的血清水平显著高于3个月后的水平（配对t检验，P < 0.001）。其余16例患者3个月时的血清水平显著高于2周时的水平（P < 0.01）。
